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Background: In patients with left ventricular (LV) dysfunction, response to medical therapy is variable. Reasons why some recover left ventricular 
function while others decompensate are not well understood. Genomic variants may help predict this differential response.
Methods: We performed a multi-phased genomic study to identify common variants associated with improvement in LV function. Of 1200 patients 
with heart failure screened at Stanford Hospital and the Palo Alto VA, 29 patients had an absolute improvement of 20% in LV function. 37 age, sex 
and ethnicity-matched patients with decompensation leading to heart transplant were identified. The results of a genome wide association study 
using the Illumina 550K platform comparing these groups were combined with publicly-available gene expression studies of heart failure tissue as 
well as semantic literature mining of Pubmed abstracts to create a customized 1536 genetic variant chip. Of the remaining patients screened, 137 
patients with an absolute 10% improvement in LV function and 472 controls were successfully genotyped with the customized chip. Association with 
LV functional improvement was tested using an additive logistic regression model adjusted for age, sex and race.
Results: The genomic variant rs7767652 was associated with improvement in LV function (OR 0.40, p=3.29 X10-5, which reaches Bonferoni-
corrected statistical significance). This variant lies 2,000bp upstream of the hypocretin (orexin) receptor 2 gene.
Conclusion: Using a multi-phased genomic analysis that incorporates gene expression and literature data sources, we identified a genomic variant 
associated with improvement in LV function. Since dramatic improvement in LV function is often due to response to medications, this variant may 
modulate pharmacologic response. Further studies to identify its functional significance are needed.
